Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus thalidomide in previously treated solid tumors
ChiCTR2100052588Phase 2Not yet recruiting
- Sponsor
- Lixin County People's Hospital
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and thalidomide in liver cancer, bronchial carcinoma, gastric cancer (GC) and 3 more, sponsored by Lixin County People's Hospital. Primary endpoint: progression-free survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
camrelizumabthalidomide
03
Conditions
liver cancerbronchial carcinomagastric cancer (GC)colorectal cancer (CRC)esophageal cancer
Beyond the preview
Go deeper on ChiCTR2100052588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052588.